hline1.jpg (2302 bytes) PRESS ROOM hline1.jpg (2302 bytes)

Aurobindo receives second ANDA approval from US FDA for PEPFAR
Aurobindo receives the first ARV approval from US FDA
USFDA approval received for Unit VIII Facility
Aurobindo receives NABL approval for its Clinical Laboratory
Aurobindo records improved performance quarter on quarter
Successful USFDA Inspection of one more Unit
Obtains 3rd product approval from USFDA
Aurobindo in Forbes list
Best under a Billion - Asia's Rising Companies
Aurobindo receives US FDA approval for Citalopram
A robust generic product portfolio to unveil.
Aurobindo obtains two product approvals from US FDA
Records Rs.272 crore turnover in Q2
First product approval from US FDA received Foray into Regulated Market crosses first major milestone
Company scientists conferred awards
Speech by the Chairman, Mr. P. V. Ramaprasad Reddy at the Annual General Meeting on 31st July 2004
Aurobindo posts Rs.2873 Millions sales and Rs.180 Million profit
Aurobindo net profit at Rs. 127 crs surges by 23%
UK MHRA (UK MCA) approval received for Unit 3
Subscription to preferential issue of equity shares
Aurobindo Q3 PAT grows by 68% Exports soar to 51% of sales
Aurobindo gets its first CoS approval from EDQM & files DMF for Citalopram
Aurobindo's Q2 Net Profit jumps to Rs.321.5 million, spurt by 57%
Preferential Issue of Equity Shares
Aurobindo net profit spurts by 52.75% in Q1
Aurobindo crosses the landmark Net Profit of Rs.100 crores
Aurobindo's demonstration of R&D leadership in cephalosporins
Aurobindo Pharma launches cefepime
Second quarter profit jumps  41.13%
Aurobindo implementing ERP package
First quarter profit jumps 34%
Noted Cardiologist Dr. I. Satyamurthy joins Aurobindo Board
Aurobindo Pharma wins award for the best bulk drug company
Shares allotted to Templeton
Brazilian GMP certification received for the speciality generic formulations unit
Aurobindo Pharma acquires equity in Ranit Pharma
Mr. Lanka Srinivas inducted as Additional Director on Board of Aurobindo Pharma
Aurobindo Pharma launches Aztreonam for the first time in India  
Aurobindo Pharma & Citadel promote a joint venture
Aurobindo Pharma welcomes excise duty exemption on anti-HIV drugs in budget
Aurobindo launches Cefactam (Cefoperazone plus Salbactam)
4th generation Cephalosporin – Cefpirome launched
Impressive Q3 performance 
Aurobindo shareholders approve Rs.125 crore Private Placement
Templeton to pick up equity
Aurobindo Pharma Board approves Rs. 125 crore private placement
Aurobindo Pharma launches two more antiretroviral products for HIV treatment
Restructuring on track
Aurobindo introduces two more drugs for treatment of Aids
Imunus Aurobindo launches two new anti-aids drugs
Aurobindo Pharma slashes prices of anti-aids drugs
Restructuring Facilities
Income crosses Rs. 1000 crore land mark

www.aurobindo.com

Hyderabad, 1st July, 2002

Aurobindo posts Net Profit of  Rs. 68.51 crore

Aurobindo Pharma Ltd. has posted good results for the year ended 31st March, 2002.

Total Income for the year registered a growth of 4.43% and amounted to
Rs.1052.40 crores (Rs. 1007.75 crore), while Profit before depreciation, interest and tax for the year stood at Rs. 137.04  crores (Rs. 139.89 crore).

After taking into account extra-ordinary income (from sale of brands) of Rs. 10.00 crores and providing interest of Rs.42.39 crores (Rs.41.68 crore), depreciation of
Rs.15.81 crores (Rs.14.78 crore) and provision for taxation (including deferred tax and adjustment of previous years) of Rs.20.33 crore (Rs.15.12 crore), the Net Profit for the year stood at Rs.68.51 crores ( Rs.68.31 crore).

The Company has strong fundamentals and as at 31st March, 2002, Reserves and Surplus stood at Rs.340.69 crore on an equity base of Rs.20.67 crore.

The company's exports for the year amounted to Rs.495.18 crore, accounting for 47.72% of its total sales. The formulation sales registered  a growth of 61.09% and stood at Rs. 85.91 crore (53.33 crore).

In spite of  the downtime and consequent loss of production due to manufacturing facilities taken up for restructuring, the Company was able to surpass its previous year’s performance. The Company's restructuring and expansion programme is progressing as per schedule.

The Board of Directors has recommended a dividend of 30% for the year, subject to the approval of the shareholders at the AGM.

Top

________________________________________________________________